Article PDF
Avoid common mistakes on your manuscript.
References
Norwich-Eaton Pharmaceuticals (Division of Norwich-Eaton, Ltd.). 1979. Dantrium Intravenous (Dantrolene Sodium Intravenous). Product Monograph.
Snyder HR Jr,Davis CS, Bickerton RK, Halliday RP. l-[(5-Arylfurfurylidine)]amino hydantoins. A new class of muscle relaxants. J Med Chem 1967; 10: 807–10.
Lee C, Durant NN, Au E, Kau RL. Reversal of dantrolene sodium-induced depression of skeletal muscle in the cat. Anesthesiology 1981; 54: 61–5.
Ellis KO, White RL Jr,Wright GC, Wessels FL. Synthesis and skeletal muscle relaxant activity of quaternary ammonium salts of dantrolene and clodanolene. J Pharm Sci 1980; 69: 327–31.
Eitis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JF, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973; 62: 948–51.
Cotton CA, Colton JS, The action of dantrolene sodium on the lobster neuromuscular junction. Comp Biochem Physiol 1979; 64C: 153–6.
Durant NN, Lee C, Katz RL. The action of dantrolene on transmitter mobilization at the rat neuro-muscular junction. Eur J Pharmacol 1980; 68: 403–8.
Karup C. The effect of dantrolene on the enhancement and diminution of tension evoked by staircase and by tetanus in rat muscle. J Physiol 1981; 311: 389–400.
Leslie GC, Pan NJ. Effect of dantrolene sodium on twitch contractions of individual motor units in the rat. J Physiol 1981; 318: 24.
Nott MW, Bowman WC. Actions of dantrolene sodium on contractions of the tibialis anterior and soleus muscles of cats under chloralose anaesthesia. Clin Exp Pharmacol Physiol 1974; 1: 113–22.
Ellis KO, Bryant SH. Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium. Naunyn-Schmiedeberg’s Arch Pharmacol 1972; 274: 107–9.
Desmedt JE, Hainaut K, Inhibition of the intra-cellular release of calcium by dantrolene in barnacle giant muscle fibres. J Physiol 1977; 265: 565–85.
Ellis KO, Carpenter JF. Studies on the mechanism of action of dantrolene sodium: A skeletal muscle relaxant, Naunyn-Schmiedeberg’s Arch Pharmacol 1972; 275: 83–94.
Putney JW Jr,Bianchi CP. Effect of dantrolene in E-C coupling in skeletal muscle. FEBS 1973, 32; 772.
Moulds R. Comparison of the effect of sodium thiocyanate and dantrolene sodium on a mammalian isolated skeletal muscle. Br J Pharmacol 1977; 59: 129–33.
Haisall PJ, Ellis FR. A screening test for the malignant hyperpyrexia phenotype using suxa-methonium-induced contracture of muscle treated with caffeine, and its inhibition by dantrolene. Br JAnaesth 1979; 51: 753–5.
Fairhurst AS, Hamamoto V, Macri J. Modification of ryanodinc toxicity by dantrolene and halo-thane in a model of malignant hyperthermia. Anesthesiology 1980; 53: 199–204,
Okumura F, Crocker BD, Denborough MA. Site of the muscle cell abnormality in swine susceptible to malignant hyperpyrexia. Br J Anaesth 1980; 52: 377–83.
Brocklehurst L. Dantrolene sodium and ‘skinned’ muscle fibres. Nature 1975; 254: 364.
Oba T. Influence of temperature and external Ca2+ concentration upon dantrolene action on excitation-contraction coupling in frog skeletal muscle. Can J Physiol Pharmacol 1981; 59: 358–63.
Gallant EM, Godt RD, Gronert GA. Role of plasma membrane defect of skeletal muscle in malignant hyperthermia. Muscle and Nerve 1979; 2: 491–4.
Korczyn AD, Shavit S, Schlosberg I. The chick as a model for malignant hyperpyrexia. Eur J Pharmacol 1980; 61: 187–9.
Ellis KO, Carpenter JF. The effect of dantrolene sodium (F440) on skeletal muscle. Fed Proc 1971; 30: 670.
Flewelkn EH, Nelson TE, Bee DE. Effect of dantrolene on neuromuscular block by d-tubocurarine and subsequent antagonism by neostigmine in the rabbit. Anesthesiology 1980; 52: 126–30.
Morgan KG, Bryant SH. The mechanism of action of dantrolene sodium. J Pharmacol Exp Therap 1977; 201: 138–47.
Desmedt JE, Hainaut K, Dantrolene and A23187 ionophore: specific action on calcium channels revealed by the aequorin method. Biochem Pharmacol 1979; 28: 957–64.
Nelson TE, Flewellen EH. Does prior dantrolene affect the in vitro diagnosis of malignant hyperthermia susceptibility? Can Anaesth Soc J 1979; 26: 484–8.
Nelson TE, Flewellen EH. Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia. Anesthesiology 1979; 50: 118.
Flewellen EH, Nelson TE, Bee DE. Porcine malignant hyperthermia - failure of dantrolene dose response to diagnose susceptibility (halothane effect). Can Anaesth Soc J 1980; 27: 16–21.
Flewellen EH, Nelson TE. A comparison of dantrolene and procainamide on in vivo muscle twitch of malignant hyperthermia susceptible pigs. FEBS 1978; 37: 331.
Anderson IL, Lipicky RJ, Jones EW. Dantrolene sodium in porcine malignant hyperthermia: studies on isolated muscle strips. In: Second International Symposium on Malignant Hyperthermia (eds,Aldrete, J.A. andBritt, B.A.), Grune & Stratton, New York, p. 509–34 (1978).
Leslie GC, Part NJ. The action of dantrolene sodium on rat fast and slow muscle in vivo. Br J Pharmac 1981; 72: 665–72.
Anderson IL, Jones EW. Porcine malignant hyperthermia: effect of dantrolene sodium on in-vitro halothane-induced contraction of susceptible muscle. Anesthesiology 1976; 44: 57–61.
Anderson IL, Rawstron RE, Dunlop DJ. Screening for malignant hyperthermia susceptibility. NZ Med J 1980; 91: 417–9.
Nelson TE. Excitation-contraction coupling: a common etiologic pathway for malignant hyperthermia susceptible muscle. In: Second International Symposium on Malignant Hyperthermia (eds.Aldrete, J.A. andBritt, B.A. Grune & Stratton, New York, p. 23–36 (1978).
Rosenberg H. Dantrolene and caffeine contracture test (letter to the editor). Can Anaesth Soc J 1980; 27: 303–4.
Lambert W. Dantrolene and caffeine contracture test (letter to the editor). Can Anaesth Soc J 1980; 27: 304.
Britt BA. Unpublished data. (1981).
Sengupta C, Meyer UA, Carafoli E. Binding of dantrolene sodium to muscle intracellular membranes, FEBS 1980; 117: 37–8.
Butterfield JL, Ellis KO. Effects of dantrolene sodium, a skeletal muscle relaxant, on the contractility of cardiac and smooth muscle. Fed Proc 1973; 32: 772.
Ellis KO, Wessels FL, Carpenter JF. Effects of intravenous dantrolene sodium on respiratory and cardiovascular functions. J Pharmaceut Sci 1976; 65: 1359–63.
Ellis KO, Butterfield JL, Wessels FL, Carpenter JF. A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium - a skeletal muscle relaxant. Arch Int Pharmacodyn Ther 1976; 224: 118–32.
Gollan F, McDermott J. Effect of the skeletal muscle relaxant dantrolene sodium on the isolated, perfused heart (40384). Proc Soc Exp Biol Med 1979; 160: 42–5.
Bowman WC, Houston J, Khan HH, Rodger IW. Effects of dantrolene sodium on respiratory and other muscles and on respiratory parameters in the anaesthetised cat. Eur J Pharmacol 1979; 55: 293–303.
Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53: 395-423. 46 Ellis RH, Simpson P, Tatham P, Leighton, M, Williams J. The cardiovascular effects of dantrolene sodium in dogs. Anaesthesia 1975; 30: 318–22.
Ally AI, Horrobin DF, Manku MS et al. Dantro-lene blocks intracellular calcium release in smooth muscle: competitive antagonism of thromboxane A2. Can J Physiol Pharmacol 1978; 56: 520–3.
Bailey LE, Shibata S, Seriguchi DG, Dresei PE. Inhibition of the positive inotropic effect of antho-pleurin-A (AP-A) by dantrolene. Life Sciences 1980; 26: 1061–8.
Plizga A, Holl JE. Myocardial depression associated with effective refractory period prolongation after pentobarbital and procainamide but not after dantrolene.Res Comm Chem Pathol Pharmacol 1980; 28: 13–26.
Hatae J, Ohba M, Kawata M. Effects of dantrolene sodium on the excitation-contraction coupling of the mammalian and amphibian cardiac muscle. J Mol Cell Cardiol 1980; 12: 857–67.
Salata JJ, Jalife J, Effects of dantrolene sodium on the electrophysiological properties of cacine cardiac Purkinje fibers. J Pharmacol Exp Ther 1982; 220: 157–66.
Harris JD, Benson GS, Effect of dantrolene sodium on canine bladder contractility. Urology 1980; 16: 229–31,
Khalaf IM, Foley G, Elhilali MM. The effect of dantrium on the canine urethral pressure profile. Investigative Urology 1979; 17: 188–90.
Hackler RH, Broecker BH, Klein FA, Brady SM. A clinical experience with dantrolene sodium for external urinary sphincter hypertonicity in spinal cord injured patients. J Urol 1980; 124: 78–81.
Mahmoudian M, Dehpour AR, Mofakham S. Effect of dantrolene sodium on the contractility of rabbit jejunum in vitro. Eur J Pharmacol 1981; 70: 287–92.
Harrison GG. Control of the malignant hyper-pyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975; 47: 62–5.
Hall GM, Lucke JN, Lister D. Treatment of porcine malignant hyperthermia. The successful use of dantrolene in the Pietrain pig. Anaesthesia 1977; 32: 472.
Hall GM. Lucke JN, Lister D. Malignant hyperthermia — pearls out of swine? Br J Anaesth 1980; 52: 165–71.
Gronert GA, Milde JH, Theye RA. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976; 44: 488–95.
Hall LW, Trim CM, Woolfe N, Further studies on porcine malignant hyperthermia. Br Med J 1972; 2: 145.
Ellis KO. Personal communication. Norwich Eaton Pharmaceuticals, Norwich, N.Y. (1981).
Fukuchi H, Kuwata N, Seki Y, Morio M. Preparation and stability of parenteral solution of 0.4W/V% dantrolene sodium. Hiroshima J Anesthesia 1979; 15:21–4.
Fukuchi H, Morio M. Preparation of dantrolene sodium for intravenous use. Hiroshima J Anesthesia 1977; 13 (Suppl):1199.
Tomonaga F, Kobayashi T, Yago K, et al. Pharmaceutical studies of dantrolene sodium. Hiroshima J Anesthesia 1979; 15 (Suppl.):101–88.
Gronert GA, Mansfield E, Theye RA. Rapidly soluble dantrolene for intravenous use. In: Second International Symposium on Malignant Hyperthermia (eds.Aldrete, J.A. andBritt, B.A.), Grune & Stratton, N.Y., p, 535–6 (1978),
Drechsler H. Zur therapie der malignen hyperthermie. Anaesthesist 1981; 30: 257-8. 67 Editorial Dantrolene sodium approved for malignant hyperthermia. FDA Drug Bulletin 1979; 9: 27.
Ryan JF. Treatment of acute hyperthermia crises. In: International Anesthesiology Clinics: Malignant Hyperthermia. (ed. Britt, B.A.). 1979; 17: 153–68.
Mathieu A, Bogosian AJ, Ryan JF, Crone, RK, Crocker D. Recrudescence after survival of an initial episode of malignant hyperthermia. Anesthesiology 1979; 51: 454–5.
Faust DK, Gergis SD, Sokoll MD. Management of suspected malignant hyperpyrexia in an infant, Anesth Analg 1979; 58: 33–5.
Friesen CM, Brodsky JB, Dillingham MG. Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report. Can Anaesth Soc J 1979; 26: 319–21.
Liebenschutz F, Mai C, Pickerodt VWA, Increased carbon dioxide production in two patients with malignant hyperpyrexia and its control by dantrolene. Br J Anaesth 1979; 51: 899–903.
Jones SEF, Thomas CH. Malignant hyperthermia in a patient with an ankylosed jaw. Anaesthesia 1980; 35: 987–90.
Hoff B, Taylor C, Kruel J. Dantrolene therapy for malignant hyperthermia (letter to the editor). Crit Care Med 1980; 8: 699–700.
Harrison GG. Dantrolene sodium in the treatment of MH: a case report. S Afr Med J 1981; 60: 909–10.
Denborough MA. Etiology and pathophysiology of malignant hyperthermia. In: International Anesthe-siology Clinics: Malignant Hyperthermia. (ed. Britt, B.A). 1979; 17: 11–26.
Britt, BA. Malignant hyperthermia — a review. In, Handbook of Experimental Pharmacology, Pyretics and Antipyretics (ed.Milton, A.S.), Springer-Verlag, Heidelberg. 1982; p. 547–615.
Sedwick LA, Romano PE. Malignant hyperthermia. Considerations for the ophthalmologist. Surv Ophthalmol 1981; 25: 378–82.
Schvaneveldt JA, Stankiewicz JA. Malignant hyper-pyrexia: an update for the otolaryngologist. The Laryngoscope 1981; 81: 918–26.
Landauer B, Zur Behandlung der malignen Hyperthermie mit Dantrolen. Der Anaesthesist 1980; 29: 507–8.
Dohlman LE. Malignant hyperthermia: a consideration for plastic surgeons. Plastic and Reconstructive Surgery 1982; 69: 547–51.
Hopkins S. Dantrolene sodium. Nursing Mirror 1980; 151: 30.
Harrison GG. The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine. Br J Anaesth 1977, 49: 315–7.
Kerr DD, Wingard DW, Gatz EE. Prevention of porcine malignant hyperthermia by oral dantrolene. In: Second International Symposium on Malignant Hyperthermia (eds.Aldrete, J.A. andBritt, B.A.), Grune & Stratton, New York, 1978; 499–507.
Flewellen EH, Nelson TE. Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Anesthesiology 1980; 52: 303–8.
Flewelten EH, Nelson TE. Porcine malignant hyperthermia: a method to produce dantrolene prophylaxis and therapeusis. Anesthesiology 1978; 51: 1001.
Gallagher DM, Hyer RL. Effective use of dantrolene in a patient susceptible to malignant hyperthermia. J Oral Surgery 1980; 38: 438–40.
Free CW, Jaimon MPC. Pre-anaesthetic administration of dantrolene sodium to a patient at risk from malignant hyperthermia: case report. NZ Med J 1978; 88: 493–4.
Bronstein SL, Ryan DE, Solomons CC, Mahowald MC.Dantrolene sodium in the management of patients at risk from malignant hyperthermia. J Oral Surgery 1979; 37: 719–24.
Fitzgibbons DC. Malignant hyperthermia following preoperative oral administration of dantrolene. Anesthesiology 1981; 54: 73–5.
Jardon OM, Wingard DW, Barak AJ, Connolly JF. Malignant hyperthermia. A potentially fatal syndrome in orthopaedic patients. J Bone and Joint Surgery 1979; 61-A: 1064–70.
Relton JES. Anesthesia for elective surgery in patients susceptible to malignant hyperthermia. In: International Anesthesiology Clinics: Malignant Hyperthermia. (ed. Britt, B.A.). 1979; 17: 141–51,
Gronert GA. Puzzles in malignant hyperthermia. Anesthesiology 1981; 54: 1–2.
Hall GM. Editorial. Dantrolene and the treatment of malignant hyperthermia. Br J Anaesth 1980; 52: 847–9.
Pandit SK, Kothary SP, Cohen PJ. Orally administered dantrolene for prophylaxis of malignant hyperthermia. Anesthesiology 1979; 50: 156–8.
Flwellen EH, Nelson TE, Bee DE. Porcine malignant hyperthermia - failure of dantrolene dose response to diagnose susceptibility (halothane effect). Can Anaesth Soc J 1980; 27: 16–21.
Gronert GA, Thompson RL, Onofrio BM, Human malignant hyperthermia; awake episodes and correction by dantrolene. Anesth Analg 1980; 59: 377–8.
Chyatte SB, Birdsong JH. The use of dantrolene sodium in disorders of the central nervous system. Southern Med J 1971; 64: 830–4.
Gelenberg AJ, Poskanzer DC. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313–5.
Chyatte SB, Birdsong JH, Roberson DL, Dantrolene sodium in athetoid cerebral palsy. Arch Physical Med Rehab 1973; 54: 365–8.
Chyatte SB, Birdsong JH, Bergman BA. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. Southern Med J 1971; 64: 180–5.
Mayer N,Mecomber SA, Herman R. Treatment of spasticity with dantrolene sodium. Am J Physical Med 1973; 52: 18–29.
Basmajian JV, Super GA. Dantrolene sodium in the treatment of spasticity. Arch Physical Med Rehab 1973; 54: 60–5.
Chyatte SB, Basmajian JV, Dantrolene sodium: long-term effects in severe spasticity. Arch Physical Med Rehab 1973; 54; 311–5.
Wilkinson SP, Portmann B.Williams R. Hepatitis from dantrolene sodium. Gut 1979; 20: 33–6.
Molnar GE, Evangelista LA, Kathirithamby R. Dantrolene sodium in spasticity. Long-term administration in children. New York State J Med 1978; 78: 1233–7,
Fating LJ, Petusevsky ML, Snider GL. Nitro-furantoin and dantrolene; liver and lung. Ann Int Med 1980; 93: 151.
Mai J, Pedersen E, Mode of action of dantrolene sodium in spasticity. Acta Neurol Scandinav 1979; 59: 309–16.
Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. The Practitioner 1978; 221: 123–7.
Feit H. A form of chorea that responds to dantrolene sodium. Neurology 1979; 29: 1631–2.
Eberstein A, Goodgold J. Relief of myotonia by dantrolene in experimental myotonia. Exper Neurol 1978; 62: 804–9.
Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Report prepared from study being completed for publication. Kaiser Foundation Hospital, Terra Linda, California.
Joynt RL, Leonard, JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Develop Med Child Neurol 1980; 22: 755–67,
Herman R, Mayer N, Mecomber SA. Clinical pharmaco-physiology of dantrolene sodium. Am J Physical Med 1972; 51: 296–311.
Chipman M, Kaul S. The efficacy of dantrolene sodium in the treatment of spasticity. Neurology 1972; 22: 401.
Meyler WJ, Bakker H, Kok JJ, Agoston S, Wesseling H. The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. J Neurol Neurosurg Psychiat 1981; 44: 334–9,
Nogen AG. Effect of dantrolene sodium on the incidence of seizures in children with spasticity.Child’s Brain 1979; 5: 420–5.
Collier CB. Dantrolene and suxamethonium. The effect of pre-operative dantrolene on the action of suxamethonium. Anaesthesia 1979; 34: 152–8.
Platz J, Braun J, Stallenberger R. The inhibitory effect of dantrolene on the rise of serum-creatinekinase activity after combined use of halothane and suxamethonium in man. Anaesthesist 1981; 30: 338–42.
Hackl JM, Engl J, Hofstadter F etal. Possible malignant hyperthermia as reaction to an overdose of myotonolytic, antidepressive and sedative drugs. Wien Klin Wochenschrift 1981; 93: 475–9,
Delacour JL, Daoudal P, Chapoutot JL, Rocq B. Traitement du syndrome malin des neuroleptiques par le dantrolene. La Nouvelle Presse Medicale 1981;10:3572–3.
Lydiatt JS, Hill GE. Treatment of heat stroke with dantrolene. Letter to the Editor. JAMA 1981; 246:41–2.
American Hospital Formulary Service, Published by the American Society of Hospital Pharmacists, Bethesda, Md. 20814.
Agoston S. Dantrolene and suxamethonium. Letter to the editor. Anaesthesia 1980; 35: 1012–3.
Cornette M, Gillard C, Borll-Hermans G. Hépatite toxique mortelle associée a l’usage du dantrolene. Acta neurol belg 1980; 80: 336–47.
Abernathy CO, Utili R, Zimmerman HJ, Ezekiel M. The effects of dantrolene sodium on excretory function in the isolated perfused rat liver. Toxicol Appl Pharmacol 1978; 44: 441–52.
Roy S, Francis KT, Born CK, Hamrick ME. Interaction of dantrolene with the hepatic mixed function oxidase system. Res Comm Chem Pathol Pharmacol 1980; 27: 507–20.
Francis KT, Hamrick ME. Dantrolene inhibition of the hepatic mixed function oxidase system. Res Comm Chem Pathol Pharmacol 1979; 23: 69–80.
Petusevsky ML, Faling LJ, Rocklin RE, et al. Pleuropericardial reaction to treatment with dantrolene. JAMA 1979; 242: 2772–4.
Wan HH, Tucker JS. Dantrotene and lympho-cytic lymphoma. Postgrad Med J 1980; 56: 261–2.
Pembroke AC, Saxena SR, KatariaM, Zilkha KD. Acne induced by dantrolene. Br J Dermatology 1981; 104: 465–8.
Chapin JW, Lou CG, Wingard DW. Asystole after intravenous dantrolene sodium in pigs. (Letter to the Editor) Anesthesiology 1981; 54: 527–8.
Hackett LP, Dusci LJ. Determination of dantrolene sodium in human plasma using high-performance liquid chromatography. J Chromatog-raphy 1979; 179: 222–4.
Hollifield RD.Conklin JD. A spectrophotofluorometric procedure for the determination of dantrolene in blood and urine. Arch Int Pharmacodyn 1963; 174:333–41.
Hollifield RD.Conklin JD. Determination of dantrolene in biological specimens containing drug-related metabolites. J Pharm Sci 1973; 62; 271–4.
Ellis KO, Wesseis FL, Muscle relaxant properties of the identified metabolites of dantrolene. Naunyn-Schmiedeberg’s Arch Pharmacol 1978; 301: 237–40,
Cox PL, Heotis JP, Polin D, Rose GM. Quantitative determination of dantroiene sodium and its metabolites by differential pulse polarography, J Pharmaceutical Sci 1969; 58: 987–9.
Hollifield RD, Conklin JD. Determination of dantrolene in biological specimens containing drug-related metabolites. J Pharmaceutical Sci 1973; 62: 271–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Britt, B.A. Dantrolene. Can Anaesth Soc J 31, 61–75 (1984). https://doi.org/10.1007/BF03011484
Issue Date:
DOI: https://doi.org/10.1007/BF03011484